Nyrada Inc. (ASX:NYR)

Nyrada Inc. (ASX:NYR) has submitted its Phase Ia first-in-human clinical trial regulatory package to the Human Research Ethics Committee (HREC). HREC review is expected in January 2025, subject to which, volunteer recruitment will commence. More information at https://bit.ly/3VZiO5e John Moore James Bonnar

Nyrada Inc. (ASX:NYR) has received a AU$1.235m R&D Tax Incentive Rebate from the Australian Federal Government. More information at https://bit.ly/3PeX6X2. John Moore, James Bonnar

Nyrada Inc. (ASX:NYR) has provided an update on its Phase Ia healthy human volunteers trial of NYR-BI03. HREC review to be conducted in Jan 2025. Final cohort dosing expected to be completed in Jul 2025. Final trial results expected in 3QCY2025. More information at https://bit.ly/4fl57Ev. John Moore James Bonnar

Nyrada Inc. (ASX:NYR)'s Securities Purchase Plan closes at 5pm AEDT on 2 December 2024. Please take the opportunity to review the offer booklet. https://bit.ly/3YQ6VR2. James Bonnar John Moore

This morning, Nyrada Inc. (ASX:NYR) hosted an investor webinar where CEO James Bonnar presented on the Company's progress. A recording of the webinar is available at https://bit.ly/3Oq16E2. The slides are available at https://bit.ly/411j8ni. John Moore

Nyrada Inc. (ASX:NYR) CEO James Bonnar sat down for an interview with Stuart Roberts from Pitt Street Research to discuss Nyrada's progress. Thanks to Stuart and Stocks Down Under for hosting. See the video here - https://bit.ly/48MX0iH #ASX #nyrada John Moore

Nyrada Inc. (ASX:NYR) will be holding an online investor briefing on Monday 25 November 2024. CEO James Bonnar will deliver a presentation and answer investor questions. Please register at https://bit.ly/48Ed3iq

Nyrada Inc. (ASX:NYR) has today released its offer booklet for its Securities Purchase Plan. Under this plan, each Eligible CDI Holder has the opportunity to participate by applying for up to $30,000 of CDIs in Nyrada without incurring brokerage or other transaction costs. This offer is only open to Australian and New Zealand investors. Further information is available at https://bit.ly/3YQ6VR2

Walter Reed Army Institute of Research has listed Nyrada Inc. (ASX:NYR) as an Industry Partner in its Traumatic Brain Injury (TBI) program. TBI is a major threat to Soldier readiness and currently lacks any FDA-approved drug treatment options. Nyrada and WRAIR are working to fill this capability gap by developing novel, ground-breaking solutions to mitigate TBI at the point-of-injury to reduce morbidity and mortality. More information at https://bit.ly/40rS6p8 #TBI #BrainAwareness #BrainHealth James Bonnar John Moore

Please vote at Nyrada Inc. (ASX:NYR)'s coming Annual General Meeting. Nyrada will hold its Annual General Meeting on Tuesday, 12 November 2024. This will be an in-person only meeting in Sydney. CDI holders are encouraged to attend if you are able. Please register your interest at info@nyrada.com.   Date of meeting: Tuesday 12 November 2024 Time: 9.30am (AEDT) Location: Automic Group offices, Level 5, 126 Phillip Street, Sydney, NSW 2000   No matter whether you can attend, your vote is important for this meeting to proceed. To vote, please refer to the Notice of Meeting or go directly to the shareholder portal at https://lnkd.in/gC6N6f9J. Thank you for your support. John Moore James Bonnar  #AGM #biotech #Sydney #ASX